Global Recombinant Plasma Proteins Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR082403742

Publication Date:

August 7, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Plasma Proteins market size was valued at USD 95 million in 2023 and is forecast to a readjusted size of USD 109.1 million by 2030 with a CAGR of 2.0% during review period.
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report includes an overview of the development of the Recombinant Plasma Proteins industry chain, the market status of Hemophilia A (Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line), Hemophilia B (Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Recombinant Plasma Proteins.
Regionally, the report analyzes the Recombinant Plasma Proteins markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recombinant Plasma Proteins market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Recombinant Plasma Proteins market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recombinant Plasma Proteins industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recombinant Plasma Proteins market.
Regional Analysis: The report involves examining the Recombinant Plasma Proteins market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Recombinant Plasma Proteins market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Recombinant Plasma Proteins:
Company Analysis: Report covers individual Recombinant Plasma Proteins players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Recombinant Plasma Proteins This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hemophilia A, Hemophilia B).
Technology Analysis: Report covers specific technologies relevant to Recombinant Plasma Proteins. It assesses the current state, advancements, and potential future developments in Recombinant Plasma Proteins areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Recombinant Plasma Proteins market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Recombinant Plasma Proteins market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Market segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Market segment by players, this report covers
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Recombinant Plasma Proteins product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Recombinant Plasma Proteins, with revenue, gross margin and global market share of Recombinant Plasma Proteins from 2019 to 2024.
Chapter 3, the Recombinant Plasma Proteins competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Recombinant Plasma Proteins market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Plasma Proteins.
Chapter 13, to describe Recombinant Plasma Proteins research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Product Overview and Scope of Recombinant Plasma Proteins
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Recombinant Plasma Proteins by Type
1.3.1 Overview: Global Recombinant Plasma Proteins Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Recombinant Plasma Proteins Consumption Value Market Share by Type in 2023
1.3.3 Chinese Hamster Ovary (CHO) Cell Line
1.3.4 Baby Hamster Kidney (BHK) Cell Line
1.3.5 Human Embryonic Kidney (HEK) Cell Line
1.3.6 Others
1.4 Global Recombinant Plasma Proteins Market by Application
1.4.1 Overview: Global Recombinant Plasma Proteins Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hemophilia A
1.4.3 Hemophilia B
1.4.4 Von Willebrand Disease
1.4.5 Others
1.5 Global Recombinant Plasma Proteins Market Size & Forecast
1.6 Global Recombinant Plasma Proteins Market Size and Forecast by Region
1.6.1 Global Recombinant Plasma Proteins Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Recombinant Plasma Proteins Market Size by Region, (2019-2030)
1.6.3 North America Recombinant Plasma Proteins Market Size and Prospect (2019-2030)
1.6.4 Europe Recombinant Plasma Proteins Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Recombinant Plasma Proteins Market Size and Prospect (2019-2030)
1.6.6 South America Recombinant Plasma Proteins Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Recombinant Plasma Proteins Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 CSL Limited
2.1.1 CSL Limited Details
2.1.2 CSL Limited Major Business
2.1.3 CSL Limited Recombinant Plasma Proteins Product and Solutions
2.1.4 CSL Limited Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 CSL Limited Recent Developments and Future Plans
2.2 Shire (Takeda Pharmaceutical Company Limited)
2.2.1 Shire (Takeda Pharmaceutical Company Limited) Details
2.2.2 Shire (Takeda Pharmaceutical Company Limited) Major Business
2.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Product and Solutions
2.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments and Future Plans
2.3 Octapharma
2.3.1 Octapharma Details
2.3.2 Octapharma Major Business
2.3.3 Octapharma Recombinant Plasma Proteins Product and Solutions
2.3.4 Octapharma Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Octapharma Recent Developments and Future Plans
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Recombinant Plasma Proteins Product and Solutions
2.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novo Nordisk Recent Developments and Future Plans
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Recombinant Plasma Proteins Product and Solutions
2.5.4 Bayer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Bayer Recent Developments and Future Plans
2.6 Bioverativ Therapeutics, Inc. (Sanofi)
2.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Details
2.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Major Business
2.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Product and Solutions
2.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Developments and Future Plans
2.7 Aptevo Therapeutics
2.7.1 Aptevo Therapeutics Details
2.7.2 Aptevo Therapeutics Major Business
2.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Product and Solutions
2.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Aptevo Therapeutics Recent Developments and Future Plans
2.8 Pharming Group
2.8.1 Pharming Group Details
2.8.2 Pharming Group Major Business
2.8.3 Pharming Group Recombinant Plasma Proteins Product and Solutions
2.8.4 Pharming Group Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pharming Group Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Recombinant Plasma Proteins Product and Solutions
2.9.4 Pfizer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Recombinant Plasma Proteins Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Recombinant Plasma Proteins by Company Revenue
3.2.2 Top 3 Recombinant Plasma Proteins Players Market Share in 2023
3.2.3 Top 6 Recombinant Plasma Proteins Players Market Share in 2023
3.3 Recombinant Plasma Proteins Market: Overall Company Footprint Analysis
3.3.1 Recombinant Plasma Proteins Market: Region Footprint
3.3.2 Recombinant Plasma Proteins Market: Company Product Type Footprint
3.3.3 Recombinant Plasma Proteins Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Recombinant Plasma Proteins Consumption Value and Market Share by Type (2019-2024)
4.2 Global Recombinant Plasma Proteins Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Recombinant Plasma Proteins Consumption Value Market Share by Application (2019-2024)
5.2 Global Recombinant Plasma Proteins Market Forecast by Application (2025-2030)
6 North America
6.1 North America Recombinant Plasma Proteins Consumption Value by Type (2019-2030)
6.2 North America Recombinant Plasma Proteins Consumption Value by Application (2019-2030)
6.3 North America Recombinant Plasma Proteins Market Size by Country
6.3.1 North America Recombinant Plasma Proteins Consumption Value by Country (2019-2030)
6.3.2 United States Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
6.3.3 Canada Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
6.3.4 Mexico Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Recombinant Plasma Proteins Consumption Value by Type (2019-2030)
7.2 Europe Recombinant Plasma Proteins Consumption Value by Application (2019-2030)
7.3 Europe Recombinant Plasma Proteins Market Size by Country
7.3.1 Europe Recombinant Plasma Proteins Consumption Value by Country (2019-2030)
7.3.2 Germany Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
7.3.3 France Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
7.3.5 Russia Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
7.3.6 Italy Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Plasma Proteins Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Recombinant Plasma Proteins Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Region
8.3.1 Asia-Pacific Recombinant Plasma Proteins Consumption Value by Region (2019-2030)
8.3.2 China Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8.3.3 Japan Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8.3.4 South Korea Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8.3.5 India Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
8.3.7 Australia Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
9 South America
9.1 South America Recombinant Plasma Proteins Consumption Value by Type (2019-2030)
9.2 South America Recombinant Plasma Proteins Consumption Value by Application (2019-2030)
9.3 South America Recombinant Plasma Proteins Market Size by Country
9.3.1 South America Recombinant Plasma Proteins Consumption Value by Country (2019-2030)
9.3.2 Brazil Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
9.3.3 Argentina Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Plasma Proteins Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Recombinant Plasma Proteins Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Country
10.3.1 Middle East & Africa Recombinant Plasma Proteins Consumption Value by Country (2019-2030)
10.3.2 Turkey Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
10.3.4 UAE Recombinant Plasma Proteins Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Recombinant Plasma Proteins Market Drivers
11.2 Recombinant Plasma Proteins Market Restraints
11.3 Recombinant Plasma Proteins Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Recombinant Plasma Proteins Industry Chain
12.2 Recombinant Plasma Proteins Upstream Analysis
12.3 Recombinant Plasma Proteins Midstream Analysis
12.4 Recombinant Plasma Proteins Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂